The 'crucial' growth metric that makes CSL shares a buy today

A leading expert points to a critical growth metric that could boost CSL shares in 2025.

| More on:
Cropped shot of an attractive young female scientist working on her computer in the laboratory.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

CSL Ltd (ASX: CSL) shares can't escape the wider market sell-down today.

Shares in the S&P/ASX 200 Index (ASX: XJO) biotech stock are down 0.22% in afternoon trade on Wednesday, changing hands for $264.12 apiece.

For some context, the ASX 200 is down 0.84% at this same time.

But looking to the year ahead, Ord Minnett's Tony Paterno has an optimistic outlook on CSL stock (courtesy of The Bull).

Time to buy CSL shares?

"This biotechnology giant recently posted mixed results across its key business units in the first half of fiscal year 2025," said Paterno, who has a buy recommendation on CSL shares.

But a crucial growth metric could be set to boost the company's profitability.

According to Paterno:

Management flagged that gross margins for its plasma business Behring are expected to reach about 57% by fiscal year 2027/2028. We believe this is crucial considering Behring currently accounts for about 67% of group revenue and 63% of earnings.

Commenting on the ongoing effort to boost gross margins after CSL released its H1 FY 2025 results last month, CEO Paul McKenzie said, "In CSL Behring we will continue to focus on improving our gross margins, which will be aided by the expected completion of the RIKA roll-out across CSL Plasma by the end of the financial year."

Rounding off why he's bullish on the ASX 200 biotech stock, Paterno noted, "Recent price/earnings valuations imply an attractive entry level, particularly as CSL has traditionally traded at a steep premium to the S&P/ASX200."

CSL stock also trades on an unfranked dividend yield (part trailing, part pending) of 1.6%.

But not everyone is convinced that now is the best time to pull the trigger on CSL shares.

A more cautious outlook

MPC Markets' Mark Gardner, for example, has a hold recommendation on CSL shares (courtesy of The Bull).

"The biotechnology giant generated revenue of $US8.470 billion in the first half of fiscal year 2025, up 5% at constant currency on the prior corresponding period," Gardner said.

Despite his hold recommendation, Gardner noted the solid growth CSL achieved over the half year in its core financial metrics.

He said:

Net profit after tax of $US2.043 billion at constant currency was up 7%. Key product segments demonstrated strong growth, with immunoglobulin product sales up 15%. Albumin sales increased 9% and haemophilia product sales increased 11%.

The company's gross margin improved by 170 basis points, reflecting operational efficiency.

What's the growth outlook for CSL shares?

For the full year FY 2025, management is forecasting year on year revenue growth of 5% to 7% on a constant currency basis.

CSL expects fiscal year 2025 net profit after tax and amortisation (NPATA) to be in the range of US$3.2 billion to US$3.3 billion on a constant currency basis. That equates to profit growth of approximately 10% to 13%.

CSL shares are down 7% over the past year, not including dividends.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Young businesswoman sitting in kitchen and working on laptop.
Healthcare Shares

Why CSL shares could be a bargain buy at $240

Let's see what Bell Potter is saying about this blue chip.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

3 ASX companies that are global leaders

Numerous ASX companies have extended their reach beyond Australia to dominate in their fields.

Read more »

Three people in a corporate office pour over a tablet, ready to invest.
Broker Notes

Bell Potter just slapped a buy on this ASX 200 share offering a 30% return

Which stock is being tipped as a buy? Let's find out.

Read more »

Happy healthcare workers in a labs
Healthcare Shares

Macquarie initiates coverage of Neuren Pharmaceuticals shares; forecasts 45% upside

The broker described Neuren as a standout in the ASX biotech sector.

Read more »

A woman leans forward with her hand behind her ear, as if trying to hear information.
Healthcare Shares

Does Macquarie think Cochlear shares are a buy, hold, or sell?

Macquarie has released a new note on Cochlear following the company's FY25 profit guidance change.

Read more »

Stethoscope with a piggy bank in the middle.
Healthcare Shares

Up 18% this year, does Macquarie expect NIB shares to go higher?

This expert has a bold prediction for NIB.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why is the Mesoblast share price up 11% in June?

The ASX biotech share reached a 10-week high of $1.94 today.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Up 51% since the tariff pain, is it too late to buy Pro Medicus shares?

After rocketing higher, is the ASX healthcare share still an opportunity?

Read more »